Stockscreener 앱 받기
29.87
0.17%
-0.05
시간 외 거래:
30.10
0.23
+0.77%
전일 마감가:
$29.92
열려 있는:
$30.11
하루 거래량:
2.48M
Relative Volume:
1.37
시가총액:
$19.16B
수익:
$2.62B
순이익/손실:
$966.70M
주가수익비율:
19.91
EPS:
1.5004
순현금흐름:
$1.09B
1주 성능:
-8.79%
1개월 성능:
+3.97%
6개월 성능:
+48.39%
1년 성능:
+31.41%
1일 변동 폭
$29.82
$30.21
1주일 범위
$29.57
$33.19
52주 변동 폭
$17.23
$33.65
Genmab Adr Stock (GMAB) Company Profile
GMAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
29.87 | 18.55B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.63 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.00 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.69 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.18 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.03 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-04-01 | 다운그레이드 | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-09-04 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-08-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-15 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-12-06 | 업그레이드 | UBS | Neutral → Buy |
| 2023-11-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-11-08 | 업그레이드 | DNB Markets | Sell → Buy |
| 2023-10-18 | 개시 | Exane BNP Paribas | Underperform |
| 2023-09-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | 개시 | BTIG Research | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-31 | 개시 | UBS | Neutral |
| 2023-05-12 | 개시 | Morgan Stanley | Underweight |
| 2022-12-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-11-14 | 개시 | William Blair | Mkt Perform |
| 2022-11-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-06-24 | 개시 | BMO Capital Markets | Market Perform |
| 2022-05-02 | 개시 | Cowen | Market Perform |
| 2022-03-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-31 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-12-01 | 개시 | Berenberg | Sell |
| 2021-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | 개시 | Deutsche Bank | Buy |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | 다운그레이드 | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | 개시 | SVB Leerink | Mkt Perform |
| 2020-06-25 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | 개시 | Credit Suisse | Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-12-12 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-09-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | Morgan Stanley | Overweight |
| 2019-08-12 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Genmab Adr 주식(GMAB)의 최신 뉴스
Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
HC Wainwright Has Pessimistic View of Genmab A/S Q2 Earnings - Defense World
Genmab A/S’s (GMAB) “Buy” Rating Reiterated at HC Wainwright - Defense World
Truist Financial Corp Reduces Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Genmab A/S FY2026 EPS Estimate Reduced by Leerink Partnrs - Defense World
GMAB or TECH: Which Is the Better Value Stock Right Now? - sharewise.com
CD40 Targeting Therapy Clinical Trials Anti CD40 Antibody Therapy Market Opportunity Assessment Insight - GlobeNewswire Inc.
Q3 EPS Estimates for Genmab A/S Lowered by Leerink Partnrs - MarketBeat
31,681 Shares in Genmab A/S Sponsored ADR $GMAB Purchased by Callan Family Office LLC - MarketBeat
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Genmab A/S Sponsored ADR $GMAB Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
William Blair Brokers Lift Earnings Estimates for Genmab A/S - MarketBeat
DAVENPORT & Co LLC Grows Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Wealth Enhancement Advisory Services LLC Buys New Shares in Genmab A/S Sponsored ADR $GMAB - Defense World
QRG Capital Management Inc. Sells 8,945 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Genmab A/S (NASDAQ:GMAB) Sets New 1-Year HighHere's Why - MarketBeat
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal - sharewise.com
Genmab AS (GMAB) Stock Price, Trades & News - GuruFocus
What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now? - sharewise.com
Why Genmab Stock Popped on Friday - The Globe and Mail
Leerink Partnrs Weighs in on Genmab A/S FY2027 Earnings - Defense World
Best Momentum Stock to Buy for October 3rd - sharewise.com
Genmab A/S (NASDAQ:GMAB) Price Target Raised to $40.00 at HC Wainwright - Defense World
Genmab A/S Sponsored ADR $GMAB Stock Position Lowered by Signaturefd LLC - Defense World
New Strong Buy Stocks for October 3rd - Yahoo Finance
Leerink Partnrs Comments on Genmab A/S FY2027 Earnings - MarketBeat
Genmab A/S Updates Articles of Association to Enhance Growth Strategy - The Globe and Mail
FY2025 EPS Estimates for Genmab A/S Boosted by William Blair - MarketBeat
Park Avenue Securities LLC Acquires 832 Shares of Genmab A/S Sponsored ADR $GMAB - Defense World
TD Cowen Remains a Hold on Genmab (GMAB) - The Globe and Mail
Genmab A/S (NASDAQ:GMAB) Sets New 52-Week HighWhat's Next? - MarketBeat
TD Private Client Wealth LLC Has $130,000 Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume on Analyst Upgrade - Defense World
Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Trending tickers: Alibaba, AstraZeneca, GSK, Stellantis and Genmab - Yahoo
European Stocks Higher to Kick Off the Week - TradingView
Genmab A/S Sponsored ADR $GMAB Shares Sold by Fifth Third Bancorp - Defense World
Before the bell: futures up, Lufthansa cuts jobs, GSK CEO steps down - TradingView
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - Placera.se
Genmab A/S (NASDAQ:GMAB) Upgraded by Guggenheim to Buy Rating - Defense World
Genmab A/S Sponsored ADR $GMAB Shares Purchased by Parallel Advisors LLC - Defense World
Rhumbline Advisers Increases Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab Adr (GMAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.42%
1.39%
자본화:
|
볼륨(24시간):